ARA-290 Protocol Guide
ARA-290 (cibinetide) is an 11-amino acid peptide derived from the erythropoietin (EPO) B helix that selectively activates the innate repair receptor (IRR), a heterodimer of EPOR and beta common receptor (betacR). Unlike EPO, ARA-290 does not stimulate erythropoiesis or carry thrombotic risk, instead providing targeted neuroprotection, anti-inflammatory effects, and tissue repair signaling. Investigated in Phase 2 clinical trials for sarcoidosis-related small fiber neuropathy and diabetic neuropathy, ARA-290 has demonstrated improvements in nerve fiber density, pain scores, and metabolic parameters. This protocol covers subcutaneous dosing at 2-4mg daily, clinical trial-derived timelines, and stacking for comprehensive neuroprotective research.
Protocol Overview
- Compound
- ARA-290 (Cibinetide)
- Category
- Neuroprotection / Anti-Inflammatory
- Mechanism
- Selective innate repair receptor (IRR) agonist; activates EPOR/betacR heterodimer for neuroprotection without erythropoiesis
- Molecular Weight
- ~1,257 g/mol
- Half-Life
- ~2 minutes (rapid clearance, sustained signaling)
- Form
- Lyophilized powder (5mg vials)
- Route
- Subcutaneous
- Frequency
- 1x daily
- Cycle Length
- 4-8 weeks (clinical trials used 28 days)
Dosing Protocol
| Protocol | Dose | Frequency | Route | Duration |
|---|---|---|---|---|
| Clinical Trial Standard | 2 mg | 1x daily | SubQ | 28 days |
| Research Standard | 4 mg | 1x daily | SubQ | 4-8 weeks |
| Extended | 4 mg | 1x daily | SubQ | 8-12 weeks |
Key principle: Despite its very short plasma half-life (~2 min), ARA-290 triggers sustained intracellular signaling cascades that persist for hours. Once-daily dosing is sufficient for therapeutic effects, consistent with clinical trial protocols.
Reconstitution Guide
Standard Reconstitution
- Vial: 5mg ARA-290 lyophilized powder
- Diluent: 1mL bacteriostatic water
- Concentration: 5mg/mL
- 4mg dose: 80 units (0.8mL) on insulin syringe
- Vial yield: ~1.25 doses at 4mg
Storage & Handling
- Pre-reconstitution: Refrigerate or freeze at -20°C
- Post-reconstitution: Refrigerate at 2-8°C
- Stability: Use within 14 days once reconstituted
- Protect from light: Store in original vial
Expected Timeline
Side Effects & Monitoring
Common Side Effects
- Injection site reactions (mild erythema)
- Headache (uncommon, transient)
- Mild dizziness (rare)
ARA-290 has demonstrated an excellent safety profile in Phase 2 clinical trials with no serious adverse events attributed to the drug. It does not stimulate erythropoiesis or carry thrombotic risk.
Precautions
- No significant drug interactions identified in trials
- Monitor CBC to confirm no erythropoietic stimulation
- Limited Phase 3 data available
- Not recommended during pregnancy
Stacking Recommendations
Compatible Compounds
- BPC-157: Complementary neuroprotective and gut-brain axis support
- Semax: Cognitive neuroprotection via BDNF upregulation
- Selank: Anxiolytic and anti-inflammatory neuropeptide synergy
- Pinealon: Central nervous system bioregulation
- Alpha-lipoic acid: Antioxidant neuroprotection support
Popular Stacks
- Neuroprotective: ARA-290 4mg + Semax 600mcg + BPC-157 250mcg
- Neuropathy: ARA-290 4mg + Alpha-lipoic acid 600mg oral
- Recovery: ARA-290 4mg + Pinealon 10mg sublingual
Blood Work Recommendations
| Panel | Markers | Timing |
|---|---|---|
| CBC | Hemoglobin, hematocrit, RBC count | Baseline, Week 4, Week 8 |
| Inflammation | hs-CRP, IL-6, TNF-alpha, ESR | Baseline, Week 4, Week 8 |
| Metabolic | Fasting glucose, HbA1c, insulin | Baseline, Week 8 |
| Nerve Function | Corneal confocal microscopy, QST | Baseline, Week 8 |
CBC monitoring confirms ARA-290 does not stimulate erythropoiesis. Inflammatory markers track anti-inflammatory efficacy. Corneal confocal microscopy is the gold standard for tracking small fiber neuropathy improvement.
Related Tools & Resources
